Impact of Dietary Na+ on Glycyrrhetinic Acid-Like Factors (Kidney 11beta-(HSD2)-GALFs) in Human Essential Hypertension

Hypertension

Volumn 31, Issue 1, 1998, Pages 469-472

  Morris, David J ^a   Lo, Ying H ^a   Lichtfield, W Reid ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; GLYCYRRHETINIC ACID; GLYCYRRHETINIC ACID DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; HYDROXYSTEROID DEHYDROGENASE; ISOENZYME;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; GLYCYRRHIZA; HUMAN; KIDNEY METABOLISM; PRIORITY JOURNAL; SODIUM INTAKE; SODIUM RESTRICTION; URINARY EXCRETION; BLOOD PRESSURE; DRUG ANTAGONISM; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; ISOLATION AND PURIFICATION; KIDNEY; NON-PROGRAMMATIC; PATHOPHYSIOLOGY; URINE;

NON-PROGRAMMATIC;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIET, SODIUM-RESTRICTED; ENZYME INHIBITORS; GLYCYRRHETINIC ACID; HUMANS; HYDROXYSTEROID DEHYDROGENASES; HYPERTENSION; ISOENZYMES; KIDNEY; SODIUM, DIETARY;

EID: 0031613529     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.31.1.469     Document Type: Article

References (21)

1. Morris DJ, Semafuko WEB, Latif SA, Vogel B, Grimes CA, Sheff MF. Detection of glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension. 1992;20:356-360.
2. Lo YH, Sheff MF, Latif LA, Ribeiro C, Silver H, Morris DJ. Kidney 11beta-HSD2 is inhibited by glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension. 1997;29 (pt II):500-505.
3. Edwards CR W, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, Dekloet ER, Monder C. Localization of 11beta-hydroxysteroid dehydrogenase; tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;2:986-989.
4. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue is enzyme not receptor mediated. Science. 1988;242:583-585.
5. Arriza JW, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Houseman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-275.
6. Rusvai E, Naray-Fejes-Toth A. A new isoform of 11beta-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem. 1993;268:1-4.
7. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol. 1994;105:R11-R17.
8. + -dependent isoform of 11beta-hydroxysteroid dehydrogenase: cloning and characterization of cDNA from sheep kidney. J Biol Chem. 1994;269:25959-25962.
9. Ulick S, Levine LS, Gunczler P, Zancoato G, Ramirez LC, Rauh W, Rosler A, Bradlow HL, New MI. A syndrome of apparent mineralocorticoid excess associated with defects in peripheral metabolism on cortisol. J Clin Endocrinol Metab. 1979;49:757-764.
10. New MI, Oberfeld SE, Carey R, Grieg F, Ulick S, Levine LS. A genetic defect in cortisol metabolism as the basis for the syndrome of apparent mineralocorticoid excess syndrome. In: Mantero F, Biglieri C, Edwards CWR, eds. Endocrinology of Hypertension. New York, NY: Academic Press; 1982;85-101.
11. Monder C, Shackelton CHL, Bradlow HL, New MI, Stoner E, Iohan F, Lakshmi V. The syndrome of apparent mineralocorticoid excess: its association with 11beta-dehydrogenase and 5beta-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab. 1986;63:550-557.
12. Wilson C, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, Shackleton CHL, Funder JW, New MI. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80:2263-2266.
13. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11beta-hydroxysteroid dehydrogenase. Nat Genet. 1995;10:394-399.
14. Petrelli MD, Lim-Tio SS, Condon J, Hewison M, Stewart PM. Differential expression of nuclear 11beta-hydroxysteroid dehydrogenase type 2 in mineralocorticoid receptor positive and negative tissues. Endocrinology. 1997;138:3077-3088.
15. Tuck ML, Williams GH, Cain JP, Sullivan JM, Dluhy RG. Relation of age, diastolic blood pressure and known duration of hypertension to presence of low renin hypertension. Am J Cardiol. 1973;32:637-642.
16. Stewart PM, Valentino R, Wallace AM, Burt D, Shackleton CHL, Edwards CRW. Mineralocorticoid activity of licorice: 11beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987;2:821-824.
17. Monder C, White PC. 11beta-hydroxysteroid dehydrogenase. Vitam Horm. 1993;47:187-269.
18. Brem AS, Bina B, King T, Morris DJ. Bidirectional activity of 11beta-hydroxysteroid dehydrogenase in vascular smooth muscle cells. Steroids. 1995;20:406-410.
19. Brem AS, Bina RB, King T, Morris DJ. 11beta-OH-progesterone affects vascular glucocorticoid metabolism and contractile response. Hypertension. 1997;30:449-454.
20. Ullian ME, Walsh LG. Corticosterone metabolism and effects on angiotensin II receptors in vascular smooth muscle. Circ Res. 1995;77:702-709.
21. Takeda Y, Miyamori I, Iki K, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, Takeda R. Endogenous renal 11beta-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension. 1996;27:197-201.